GDPD4: Key Enzyme in Phosphodiesterase Family (G220032)

Target Name: GDPD4

NCBI ID: G220032

GDPD4

GDPD4: Key Enzyme in Phosphodiesterase Family

GDPD4 (Glycerophosphodiester Phosphodiesterase Domain Containing 4) is a protein that is expressed in various tissues throughout the body. It is a key enzyme in the phosphodiesterase family, which is responsible for breaking down various types of phosphates, including glucose and lipids. GDPD4 is also known as PPI-4 (Phosphodiesterase type IV), and it is localized to the endoplasmic reticulum (ER) and to the cytoplasm.

GDPD4 is a 12kDa protein that consists of 115 amino acid residues. It has a catalytic active site at its N-terminus, which allows it to catalyze the phosphodiesteration of various types of nucleotides. The protein has a distinct N-terminal and C-terminal region, which are involved in its stability and interactions with other cellular components. The N-terminal region contains a putative N-endopeptide insertion, which is involved in the formation of a stable complex with the nucleotide GDP. The C-terminal region contains a putative C-endopeptide insertion, which is involved in the formation of a stable complex with the nucleotide GTP.

GDPD4 is involved in various cellular processes, including metabolism, inflammation, and signaling. It is a key enzyme in the glycerolipid metabolism, which is responsible for the synthesis and breakdown of various types of lipids. It is also involved in the production of various signaling molecules, including nitric oxide (NO), which is a well-known neurotransmitter that plays a role in cardiovascular and respiratory function.

In addition to its role in metabolism, GDPD4 is also involved in inflammation. It has been shown to be involved in the regulation of various cellular processes that are involved in inflammation, including the production of pro-inflammatory cytokines and the regulation of cellular immune responses.

As a drug target, GDPD4 is of interest because of its involvement in various cellular processes that are involved in disease development and progression. For example, it is involved in the regulation of nitric oxide production, which is important for cardiovascular health. It is also involved in the production of various signaling molecules, including NO, which is important for the regulation of blood flow and the maintenance of cellular homeostasis.

In addition to its potential therapeutic applications, GDPD4 is also of interest as a biomarker for various diseases. For example, it is has been shown to be involved in the development of various types of cancer, including breast, ovarian, and prostate cancer. It is also involved in the regulation of cellular processes that are involved in aging, including the production of various types of DNA damage and the regulation of cellular apoptosis.

In conclusion, GDPD4 is a protein that is expressed in various tissues throughout the body and is involved in various cellular processes, including metabolism, inflammation, and signaling. It is a key enzyme in the phosphodiesterase family and has a significant impact on cellular homeostasis. As a drug target and biomarker, GDPD4 is of interest for the development of new therapeutic approaches for various diseases.

Protein Name: Glycerophosphodiester Phosphodiesterase Domain Containing 4

The "GDPD4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GDPD4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets